RT Journal Article
SR Electronic
T1 Tumor response from durvalumab (MEDI4736) + tremelimumab treatment in patients with advanced non-small cell lung cancer (NSCLC) is observed regardless of PD-L1 status
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP P193
DO 10.1186/2051-1426-3-S2-P193
VO 3
IS Suppl 2
A1 Rizvi, Naiyer
A1 Chaft, Jamie
A1 Balmanoukian, Ani
A1 Goldberg, Sarah B
A1 Sanborn, Rachel E
A1 Steele, Keith E
A1 Rebelatto, Marlon C
A1 Gu, Yu
A1 Karakunnel, Joyson J
A1 Antonia, Scott
YR 2015
UL http://jitc.bmj.com/content/3/Suppl_2/P193.abstract